BioMarin Pharmaceuticals volume is increasing?

BioMarin Pharmaceutical Inc (BMRN)

 Biomarin has a 4 star rating in the S&P, and there are conflicting reports by the analysis on whether they want to upgrade or downgrade it.  The Thomson Reuter’s report downgraded Biomarin Pharmaceuticals 9 days ago, while Second Opinion Weekly Report upgrade it from “Avoid” to “Neutral”. Interesting, the stock trade volume has increased in the last few days, just a few weeks before the new earnings report. So, unless the people buying the stock have insight into BioMartin, which we know does happen, many people may be “guessing” on the outcome to this coming Earnings. Based on what I have read, they have alot of interesting drugs in their pipeline, and have been hiring several new scientists (albeit not me though :( ) I think there is a good chance that the earnings will improve over last quarter. Does anyone want to discuss this?

So what is Biomartin Pharmaceutical company about?  BioMarin develops and commercializes pharmaceuticals for serious diseases and medical conditions. (Scottrade being vague, actually the company focuses alot on the regulation and synthesis of sugars that attached to proteins, aka glycosylation).  As of December 31, 2011, its product portfolio includes four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). As of December 31, 2011, BioMarin conducted clinical trials on a number of investigational product candidates for the treatment of various diseases, including GALNS, an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A); PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU); BMN-701, an enzyme replacement therapy for Pompe disease; BMN-673, an orally available poly (ADP-ribose) polymerase, or PARP inhibitor for the treatment of patients with certain cancers, and BMN-111 CNP for Achondroplasia (Information complements of Scottrade and Biomartin’s website http://www.bmrn.com/pipeline/index.php ).

Check out this website if you like e-books for kindle: http://www.wondersofkindle.com

*** Please support my blog by clicking and viewing the ads for a few minutes. This does not obligate you to buy, but does provide me with a few cents of income. Thanks! (poor scientist and professor)